Mei Wei, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer, as demonstrated in the DESTINY-Breast01 trial.
Mei Wei, MD, an internal medicine specialist at University of Utah Health, discusses the efficacy of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive breast cancer, as demonstrated in the phase 2 DESTINY-Breast01 trial (NCT03248492).
A significant progression-free survival benefit was observed with the antibody-drug conjugate in the heavily pretreated patient population, Wei says. Additionally, the agent showed promise in patients who with brain metastases, Wei notes.
Importantly, in patients who had received previous treatment for their brain metastases, the median overall survival had not yet been reached, Wei concludes.